Profusa (NASDAQ:PFSA) Posts Quarterly Earnings Results

Posted by Brian Himes on Aug 20th, 2026

Profusa (NASDAQ:PFSA – Get Free Report) issued its earnings results on Wednesday. The company reported ($151.80) EPS for the quarter, FiscalAI reports.

Profusa Stock Down 50.6%

Shares of NASDAQ PFSA opened at $13.57 on Thursday. Profusa has a 52 week low of $3.22 and a 52 week high of $5,190.00. The firm’s fifty day moving average is $10.21 and its 200 day moving average is $79.95. The company has a market cap of $678,500.00, a price-to-earnings ratio of -0.00 and a beta of 0.52.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Profusa from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Get Our Latest Report on PFSA

Insider Buying and Selling

In other Profusa news, major shareholder Financial Lp Hrt sold 10,602 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $3.56, for a total transaction of $37,743.12. Following the completion of the sale, the insider owned 18,549 shares of the company’s stock, valued at $66,034.44. This represents a 36.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have acquired 4,308 shares of company stock worth $16,594. Corporate insiders own 0.76% of the company’s stock.

Key Stories Impacting Profusa

Here are the key news stories impacting Profusa this week:

Neutral Sentiment: Trading in PFSA was repeatedly paused on August 18 under Nasdaq’s “Limit Up-Limit Down” (LULD) mechanism. These pauses are triggered when a stock moves outside permitted price bands and do not, by themselves, indicate a fundamental company development, but they underscore unusually volatile trading conditions.
Negative Sentiment: Profusa reported quarterly earnings of -$151.80 per share on August 19. The severe per-share loss is likely the primary fundamental reason for the stock’s weakness, particularly given the company’s very small market capitalization and speculative trading profile. Profusa earnings and stock information
Negative Sentiment: The combination of a substantial reported loss, repeated LULD halts and trading volume well above the company’s average suggests heightened investor risk and potential difficulty establishing a stable valuation.

Profusa Company Profile

(Get Free Report)

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.